Welcome to our dedicated page for Kane Biotech news (Ticker: KNBIF), a resource for investors and traders seeking the latest updates and insights on Kane Biotech stock.
Kane Biotech Inc. reports developments tied to its antimicrobial wound care business, including commercialization of the revyve product line in the United States and Canada. The company is developing and marketing wound care treatments that target biofilms and wound bacteria, with revyve Antimicrobial Wound Gel, revyve Antimicrobial Wound Gel Spray, and revyve Antimicrobial Skin and Wound Cleanser holding U.S. FDA 510(k) clearance; the gel and gel spray are also approved by Health Canada.
Recurring news includes financial results, distribution and sales-agent agreements, regulatory and quality-system updates, and scientific publications or conference presentations involving chronic wound and burn care research. Company updates also discuss operating expenses, continuing operations, and the discontinued animal health contract manufacturing activities that have affected recent results.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.